Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib. Zhao J, Lin G, Zhuo M, Fan Z, et al. Lung Cancer 2020;141:114-118.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao J, Lin G, Zhuo M, Fan Z, et al. Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib. Lung Cancer 2020;141:114-118.
PMID: 31839416